Zenith Global embeds directly into life sciences companies — finance, clinical, commercial, and strategic — all connected under one roof.
Our founding belief
"The best fundraises don't start with investor outreach — they start with building a business that's already diligence-ready."
Science breakthroughs stall when the operational foundation isn't built to support them. Most life sciences founders are world-class researchers facing CRO overcharges, messy cap tables, wrong hires, and capital strategies assembled in a panic six weeks before the pitch.
Zenith was built backwards from the exit. We embed at Seed and stay through NDA submission — finance first, clinical next, commercial when ready — so your science reaches its full value.
Lavine Hemlani
CEO & Founder, Zenith Global
Our process
Most consulting is reactive. Zenith is built backwards from your exit.
The reactive way
Problem surfaces mid-engagement after dollars are spent
Hire reactively; generalist advisors patch holes with no unified strategy
Financial model built when asked — not milestone-based, not clinical
Data room assembled 8 weeks before close; investors find discrepancies
The Zenith way
Start with a free audit — find the gaps before they cost you
Activate the right capability milestone by milestone: finance first, clinical next
Build the architecture backward from your exit — forecasts aligned to milestones and valuation targets
Raise from a position of strength with a diligence-ready business and data room
The team
Life sciences specialists with 25+ operators ready to deploy for every business need.
Everett Kamin
BioCapital Network & Digital Health
Paul Sargeant
Life Sciences CFO
Christian Parrish
Biotech Investment Banking
Thomas Hess
Fractional CFO
Lin Chan
Startup Finance
Strategic advisors & board
Advisors behind billions in capital raises, major exits, FDA pathways, and global healthcare expansion.
Dr. Tomasz
Global Health & M&A
CEO, Freyr Health; UN Ambassador, Sustainable Health Development. Founded and scaled global AI healthtech ventures.
George
Deal Volume
$10B+ deal volume across healthcare transactions. Raised billions across multiple M&A transactions.
Ian Akash Morrison
CoreWeave / IPO
Led CoreWeave to $30B+ valuation and Nasdaq IPO. Co-founder, oncology biotech Avesta76 Therapeutics.
Evan Meagher
Venture Partner
Venture Partner: Millennia Capital, 10X Capital, Modi Ventures. Facilitated $540M+ in startup funding.
Jimmy Ku
Healthcare Ventures
Ex-CSO, $250M NASDAQ biotech; multiple successful exits. Builds and funds early-stage healthcare ventures, Optio.
Institutional backgrounds
Client outcomes
Helping science-led companies raise capital, improve financial performance, and scale confidently.
"Zenith redesigned our investor deck and refined our fundraising narrative, helping present a stronger investment story for our $25M capital raise."
Biotech — $25M raise
"Zenith improved our pricing strategy, financial planning, and profitability, creating a stronger foundation to scale following our $11M raise."
Digital Health — $11M raise
"Zenith strengthened our financial planning and optimized R&D tax credits, helping maximize non-dilutive funding to support our ~$5M growth journey."
Life Sciences — non-dilutive capital
"Zenith developed an acquisition evaluation framework that enabled faster M&A decisions and financial scenario modelling, supporting Apollo's continued growth following $45M+ raised."
MedTech — $45M+ raised
"Zenith helped us build an investor-ready operating model and growth scenarios that strengthened our Series A fundraising preparation."
HealthTech — Series A preparation
"Zenith delivered a multi-region financial model, valuation framework, and fundraising strategy that strengthened the company's $10M capital raise and investor positioning."
Medical Device — $10M raise
Ecosystem partners
Zenith clients access partners across clinical development, AI, and global health data.
Vantage
Clinical Trial Partner
FDA-aligned trials in Kazakhstan at 20–30% of US cost. Government-backed site activation, ICH GCP compliance, and sovereign patient access across the CIS region.
Allos
Causal AI · Drug Formulation
Causal AI platform leveraging proprietary CMC data to optimize reformulation programs — cutting experiments by 60%, timelines by 40%, and saving up to $15M per program.
Freyr Health
Global Health Data Platform
Unified Health Record platform consolidating patient data across 100+ countries — enabling trial recruitment, real-world evidence generation, and longitudinal patient monitoring at scale.
Merova Healthcare
GCC Healthcare Platform
First-of-its-kind integrated MedTech investment, manufacturing, and marketing platform in the GCC — enabling Zenith clients to access MENA markets through a single trusted relationship.
Global footprint
San Francisco
BD Office
New York
BD Office
Boston
Client Office
London
CFO Office
UAE
Client Office
Hong Kong
Client Office
India
Operations
Who we serve
Zenith delivers the greatest impact when founders have breakthrough science, a defined growth path, and the ambition to build globally.
Funding stage
Seed to Pre-Series B. $3–30M raised in the last 24 months.
Domain
Biotech, biopharma, medtech, digital health, or life sciences platform.
Founder profile
Science-first brain — PhD, MD, or deep domain expertise. No full-time CFO or COO yet.
Geography
US, UK, EU, or GCC. Expanding into new markets and needing the infrastructure.
Runway
18–30 months. Has capital to deploy but needs it to work harder.
Next milestone
IND filing, Series A, partnership, or regulatory submission defined.
Book a strategy session to understand how our integrated life sciences platform can support your next stage of growth.
lavine@zenith-grp.co
+971 50 887 4608
zenithglobal.io